MTNR1B

Melatonin receptor 1B

Score: 0.639 Price: $0.64 High Druggability Status: active Wiki: MTNR1B

🧠 Neurodegeneration

HYPOTHESES

2

PAPERS

17

KG EDGES

25

DEBATES

1

3D Protein Structure

🧬 MTNR1B — PDB 6ME2 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

High

Score: 0.90

Clinical Stage

Approved

Target Class

Gpcr

Safety

0.80

Druggability Analysis

Drug Development1.00

Structural Tractability0.70

Target Class0.85

Safety Profile0.80

Key Metrics

PDB Structures:

5

Known Drugs:

3

Approved:

3

In Clinical Trials:

0

Drug Pipeline (3 compounds)

3 Approved

Druggability Rationale: MTNR1B is highly druggable (0.90 score) due to its well-characterized GPCR architecture with multiple crystal structures available (5 PDB entries at 2.8Å resolution), established chemical matter from three approved drugs, and proven G-protein coupling mechanism. The target's precedent with melatonin, ramelteon, and agomelatine demonstrates clear translational pathways from lead identification through clinical approval.

Mechanism: Small molecule agonists that activate G-protein coupled receptor signaling

Drug Pipeline (3 compounds)

3 Approved

Known Drugs:

Melatonin (approved) — sleep disorders

Ramelteon (approved) — insomnia

Agomelatine (approved) — depression

Structural Data:

PDB (5) ✓AlphaFold ✓Cryo-EM ✓

6ME6 6ME7 6ME8 6ME9 7VH0

UniProt: P49286

🧬 3D Protein Structure

🧬 MTNR1B — PDB 6ME2 Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

MTNR1B selectivity versus the closely related MTNR1A isoform represents the primary selectivity challenge, as both receptors share high sequence homology and overlapping pharmacology; however, approved drugs demonstrate achievable selectivity profiles. Off-target binding to other GPCRs or melatonin pathway proteins requires careful evaluation to avoid unwanted circadian or hormonal effects.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active

1

Completed

7

Total Enrollment

860

By Phase

NA: 5 · PHASE1: 1 · PHASE2: 1 · Unknown: 1

Anger Control Training for Youth With Tourette Syndrome Completed

NA NCT00486551 n=26

Tourette Syndrome, Chronic Tic Disorder, Oppositional Defiant Disorder

Interventions: Anger control training

Sponsor: Yale University | Started: 2001-08

Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease Recruiting

NA NCT06909045 n=130

Deep Brain Stimulation, Parkinson Disease

Interventions: Adaptive DBS, Continue DBS

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC | Started: 2026-01-27

Expiratory Muscle Training in Patients With Parkinson's Disease Completed

PHASE1 NCT00843739 n=90

Parkinson's Disease

Interventions: EMST - Active Treatment, sham EMST

Sponsor: University of Florida | Started: 2004-01

Study of the Follow-up of Stroke Treated With Anticoagulants Completed

Unknown NCT03292575 n=441

Stroke

Interventions: Anticoagulants

Sponsor: Centre Hospitalier Universitaire Dijon | Started: 2016-01

Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease Completed

NA NCT01924312 n=80

Cerebrovascular Disease, Mild Cognitive Impairment

Interventions: Heart Health Intervention

Sponsor: Gregory Jicha, 323-5550 | Started: 2013-05

Effects of Modern Board Games on Well Being in Older Adults Completed

NA NCT06306365 n=35

Executive Functions

Interventions: Modern board game-based learning

Sponsor: European University Miguel de Cervantes | Started: 2024-02-07

Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol Completed

NA NCT02260167 n=25

Alzheimer's Disease, Dementia

Interventions: A mix of natural treatments and medicati

Sponsor: Practitioners Alliance Network | Started: 2014-09

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) Completed

PHASE2 NCT03987295 n=33

Frontotemporal Dementia

Interventions: AL001

Sponsor: Alector Inc. | Started: 2019-09-27

Linked Hypotheses (0)

No linked hypotheses

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Knowledge Graph (20)

associated with (3)

MTNR1B→neurodegenerationADRA2A→MTNR1BTCF7L2→MTNR1B

co discussed (11)

OCLN→MTNR1BAPOE→MTNR1BLRP1→MTNR1BLDLR→MTNR1BTFR1→MTNR1B

▸ Show 6 more

AQP4→MTNR1BMTNR1A→MTNR1BMTNR1B→CAV1MTNR1B→ABCB1MTNR1B→FCGRTMTNR1B→CLDN5

implicated in (1)

MTNR1B→neurodegeneration

interacts with (4)

LRP1→MTNR1BMTNR1A→MTNR1BMTNR1B→LRP1MTNR1B→MTNR1A

targets (1)

h-7e0b5ade→MTNR1B

Debate History (1)

Should MTNR1B (Melatonin receptor 1B) be prioritized as a therapeutic target for2026-04-21